By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ChromaDex, Inc. 

10005 Muirlands Boulevard
Suite G, First Floor
Irvine  California  92618  U.S.A.
Phone: 949-419-0288 Fax: 949-419-0294



Company News
ChromaDex, Inc. Appoints Former GlaxoSmithKline (GSK) Executive, Jeff Baxter, To Its Board Of Directors 4/20/2015 8:54:22 AM
ChromaDex, Inc. Release: Published Study Shows Topical Treatment With Pterostilbene Effectively Protects Hairless Mice Against UVB Radiation-Induced Skin Damage And Carcinogenesis 4/10/2015 8:29:57 AM
ChromaDex, Inc. Appoints Former Nestle Executive, Steve Allen, As Chairman 3/3/2015 8:48:27 AM
ChromaDex, Inc.'s NIAGEN Nicotinamide Riboside Meets Primary Endpoint In First Human Clinical Study 2/11/2015 7:32:37 AM
ChromaDex, Inc. CEO To Present At The Sidoti & Company, LLC Emerging Growth Institutional Investor Forum On January 12th 1/6/2015 9:22:58 AM
NIH Publishes Results Of Preclinical Collaboration With ChromaDex, Inc. Showing Potential Benefit Of Nicotinamide Riboside 12/10/2014 7:29:42 AM
ChromaDex, Inc. Receives $750,000 Cash From Previous Sale Of Its Bluscience Line 12/3/2014 11:48:54 AM
ChromaDex, Inc. Licenses Exclusive Worldwide Patent Rights From The University Of Mississippi For Microalgae Technology Targeting Immune Support 12/2/2014 11:13:58 AM
ChromaDex, Inc. Announces Two Patent Issuances For Novel Ingredient, Pterostilbene 11/24/2014 10:37:35 AM
University of Birmingham Receives Grant From Wellcome Trust To Support Human Research On ChromaDex, Inc.s NIAGENĀ® Nicotinamide Riboside 11/17/2014 12:14:29 PM